Reproductive System Neoplasm

In a phase 2 trial, patients with metastatic castration-resistant prostate cancer harboring DNA damage repair (DDR) gene aberrations were treated with olaparib. In gene testing, samples from tumor tis… (full text at CIViC)

Open in CIViC

This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC)

PMID 38049622 · Fizazi et al., 2024 · Open in CIViC

Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines. Concentration-dependent antiproliferati… (full text at CIViC)

PMID 21278246 · Konecny et al., 2011 · Open in CIViC

Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer. In-vitro, silencing of CFLAR led to sensitization of two prostate carcinoma… (full text at CIViC)

PMID 22623731 · McCourt et al., 2012 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

Meta-analysis linking CHEK2 1100delC to a higher risk in prostate cancer ((OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00) ).

PMID 26629066 · Wang et al., 2015 · Open in CIViC

Meta-analysis linking CHEK2 1100delC to a higher risk of prostate cancer (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00).

PMID 26629066 · Wang et al., 2015 · Open in CIViC

Meta-analysis of 4 retrospective studies linked CHEK2 I157T to a higher risk of prostate cancer (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00).

PMID 26629066 · Wang et al., 2015 · Open in CIViC

Meta-analysis of 2 studies of CHEK2 and prostate cancer showing that the IVS2+1G>A mutation is irrelevant as a predictor of prostate cancer.

PMID 26629066 · Wang et al., 2015 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC)

PMID 38049622 · Fizazi et al., 2024 · Open in CIViC

COL1A1::PDGFB fusion is typically found in dermatofibrosarcoma protuberans, but this study revealed it could appear in uterine sarcoma, and the presence of this fusion was suggested as a feature for a… (full text at CIViC)

PMID 30877273 · Croce et al., 2019 · Open in CIViC

Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were va… (full text at CIViC)

PMID 26261420 · Kohli et al., 2015 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in D1709E… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1709G.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with one mutation in a Juvenile ovarian granulosa-cell tumor (1/14; 7%). This individual had a somat… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was p… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were ten mutations in D1709N… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1810H.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1810N.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%).Two Sertoli-Lydig cell tumors harbo… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). Of the eight mature teratomas that were evaluated, one had a somatic mutation in D1810Y.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian Sertoli–Leydig cell tumors. These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K.… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were five mutations in E1705… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in E1813G.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in E1813K.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

E1813 residue has been described as a hotspot for somatic missense mutations in DICER1.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was p… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two patients with E1813… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian Sertoli–Leydig cell tumors. These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K.… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC

In an analysis of 107 patients enrolled in the International Ovarian and Testicular Stromal Tumor Registry, 5 had gynandroblastoma (14-32 yo). 4 of the 4 gynandroblastoms with material available for … (full text at CIViC)

PMID 29037807 · Schultz et al., 2017 · Open in CIViC

A sequencing analysis of the DICER1 RNase IIIb region in nonepithelial ovarian neoplasms revealed a striking concentration of somatic mutations at residues required for metal binding within the cataly… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

Genomic analysis identified DICER1 RNase IIIb domain hotspot mutations in 3 of 16 cases of gynandroblastoma, leading the authors to suggest that DICER1 hotspot mutations are a key driver in a subset o… (full text at CIViC)

PMID 29660837 · Wang et al., 2018 · Open in CIViC

In an analysis of 107 patients enrolled in the International Ovarian and Testicular Stromal Tumor Registry, 5 had gynandroblastoma (14-32 yo). 4 of the 4 gynandroblastoms with material available for … (full text at CIViC)

PMID 29037807 · Schultz et al., 2017 · Open in CIViC

DNMT1 expression (mRNA expression from an independent study) correlated with sensitivity to decitabine (ρ, −0.443, Pearson regression analysis) in this preclinical study of 45 solid tumor cell lines. … (full text at CIViC)

PMID 25968887 · Stewart et al., 2015 · Open in CIViC

The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EO… (full text at CIViC)

PMID 22139083 · Ratner et al., 2012 · Open in CIViC

In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.

PMID 21730982 · Iida et al., 2011 · Open in CIViC

A variant of EGFR with exon 4 deletion (de4 EGFR) enhanced the invasiveness and cisplatin resistance of epithelial ovarian cancer cell lines (SKOV3, CAOV3, ES2) in vitro when compared with wild-type E… (full text at CIViC)

PMID 23764753 · Zhang et al., 2013 · Open in CIViC

A 33-year-old Han Chinese woman has been associated with an NTRK fusion cervical sarcoma which was positive for Pan-TRK by immunohistochemistry (IHC) analysis. However, FISH for NTRK1 was negative. Th… (full text at CIViC)

PMID 35572973 · Dang et al., 2022 · Open in CIViC

Patients with high-grade serous ovarian cancer (HGSOC) and EMSY overexpression (n = 265) received platinum-based first-line chemotherapy. When comparing patients with high and low EMSY expression, usi… (full text at CIViC)

PMID 31154673 · Hollis et al., 2019 · Open in CIViC

In a preclinical study of uterine cancer cell lines resistant to EphA2 inhibitors (HEC-1A, Ishikawa, RL-95), EphA2-positive cells treated with the MEK inhibitor trametinib restored sensitivity to dasa… (full text at CIViC)

PMID 34391578 · Wu et al., 2021 · Open in CIViC

The identification of tumor-suppressor genes in solid tumors by classical cancer genetics methods is difficult and slow. Nonsense-mediated RNA decay microarrays were combined with array-based compara… (full text at CIViC)

PMID 15300251 · Huusko et al., 2004 · Open in CIViC

The EphB2 gene has been implicated as a tumor suppressor gene somatically altered in both prostate cancer (PC) and colorectal cancer. A set of 341 single nucleotide polymorphisms (SNPs) encompassing … (full text at CIViC)

PMID 21603658 · Robbins et al., 2011 · Open in CIViC

In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient… (full text at CIViC)

PMID 15746676 · Santin et al., 2005 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the … (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC